{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:22:18Z","timestamp":1790256138978,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772965"],"award-info":[{"award-number":["81772965"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key R&D program of China","award":["2018YFA0800304"],"award-info":[{"award-number":["2018YFA0800304"]}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["19JC1411100"],"award-info":[{"award-number":["19JC1411100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Municipal Commission of Health and Family Planning","award":["2017BR018"],"award-info":[{"award-number":["2017BR018"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.cellsig.2020.109775","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T03:17:15Z","timestamp":1599535035000},"page":"109775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors"],"prefix":"10.1016","volume":"75","author":[{"given":"Yuan","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yebin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4834-9335","authenticated-orcid":false,"given":"Fa-Xing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cellsig.2020.109775_bb0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0092-8674(94)90396-4","article-title":"The ubiquitin-proteasome proteolytic pathway","volume":"79","author":"Ciechanover","year":"1994","journal-title":"Cell"},{"issue":"6835","key":"10.1016\/j.cellsig.2020.109775_bb0010","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/35077213","article-title":"Proliferation, cell cycle and apoptosis in cancer","volume":"411","author":"Evan","year":"2001","journal-title":"Nature"},{"issue":"Pt 1","key":"10.1016\/j.cellsig.2020.109775_bb0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1042\/BST0350012","article-title":"Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy","volume":"35","author":"Goldberg","year":"2007","journal-title":"Biochem. Soc. Trans."},{"issue":"5","key":"10.1016\/j.cellsig.2020.109775_bb0020","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0092-8674(94)90462-6","article-title":"Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules","volume":"78","author":"Rock","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2020.109775_bb0025","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.biochem.73.011303.074134","article-title":"The mammalian unfolded protein response","volume":"74","author":"Schroder","year":"2005","journal-title":"Annu. Rev. Biochem."},{"issue":"5","key":"10.1016\/j.cellsig.2020.109775_bb0030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.cellsig.2020.109775_bb0035","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2020.109775_bb0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12915-014-0094-0","article-title":"Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy","volume":"12","author":"Deshaies","year":"2014","journal-title":"BMC Biol."},{"issue":"10","key":"10.1016\/j.cellsig.2020.109775_bb0045","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma: a comprehensive overview","volume":"33","author":"Bazarbachi","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.cellsig.2020.109775_bb0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"issue":"9","key":"10.1016\/j.cellsig.2020.109775_bb0055","first-page":"2638","article-title":"The proteasome inhibitor PS-341 in cancer therapy","volume":"5","author":"Teicher","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.cellsig.2020.109775_bb0060","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-2850","article-title":"Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma","volume":"15","author":"Badros","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"30","key":"10.1016\/j.cellsig.2020.109775_bb0065","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cellsig.2020.109775_bb0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.cellsig.2020.109775_bb0075","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.20888","article-title":"Bortezomib in recurrent and\/or refractory multiple myeloma, Initial clinical experience in patients with impared renal function","volume":"103","author":"Jagannath","year":"2005","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.cellsig.2020.109775_bb0080","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cellsig.2020.109775_bb0085","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2217\/fon.14.30","article-title":"Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials","volume":"10","author":"Huang","year":"2014","journal-title":"Future Oncol."},{"issue":"7","key":"10.1016\/j.cellsig.2020.109775_bb0090","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2020.109775_bb0095","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.01856","article-title":"p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition","volume":"3","author":"Radhakrishnan","year":"2014","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.cellsig.2020.109775_bb0100","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1414593112","article-title":"Endo-beta-N-acetylglucosaminidase forms N-GlcNAc protein aggregates during ER-associated degradation in Ngly1-defective cells","volume":"112","author":"Huang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.cellsig.2020.109775_bb0105","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1021\/acscentsci.7b00224","article-title":"Inhibition of NGLY1 inactivates the transcription factor Nrf1 and potentiates proteasome inhibitor cytotoxicity","volume":"3","author":"Tomlin","year":"2017","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.cellsig.2020.109775_bb0110","series-title":"The Aspartyl Protease DDI2 Activates Nrf1 to Compensate for Proteasome Dysfunction, Elife 5","author":"Koizumi","year":"2016"},{"issue":"14","key":"10.1016\/j.cellsig.2020.109775_bb0115","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.cub.2014.06.004","article-title":"Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97","volume":"24","author":"Sha","year":"2014","journal-title":"Curr. Biol."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109775_bb0120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.molcel.2010.09.012","article-title":"Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop","volume":"40","author":"Steffen","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cellsig.2020.109775_bb0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.taap.2018.09.037","article-title":"Nrf1 is paved as a new strategic avenue to prevent and treat cancer, neurodegenerative and other diseases","volume":"360","author":"Yuan","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"9","key":"10.1016\/j.cellsig.2020.109775_bb0130","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nchembio.1313","article-title":"Covalent and allosteric inhibitors of the ATPase VCP\/p97 induce cancer cell death","volume":"9","author":"Magnaghi","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.cellsig.2020.109775_bb0135","doi-asserted-by":"crossref","first-page":"44912","DOI":"10.1038\/srep44912","article-title":"A structure- and chemical genomics-based approach for repositioning of drugs against VCP\/p97 ATPase","volume":"7","author":"Segura-Cabrera","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellsig.2020.109775_bb0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fonc.2016.00181","article-title":"Targeting p97 to disrupt protein homeostasis in Cancer","volume":"6","author":"Vekaria","year":"2016","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109775_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010327","article-title":"Disabling the protease DDI2 attenuates the transcriptional activity of NRF1 and potentiates proteasome inhibitor cytotoxicity","volume":"21","author":"Northrop","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.cellsig.2020.109775_bb0150","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/nprot.2014.138","article-title":"The cellular thermal shift assay for evaluating drug target interactions in cells","volume":"9","author":"Jafari","year":"2014","journal-title":"Nat. Protoc."},{"issue":"16","key":"10.1016\/j.cellsig.2020.109775_bb0155","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"issue":"15","key":"10.1016\/j.cellsig.2020.109775_bb0160","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1016\/j.bmcl.2016.06.013","article-title":"Enriching screening libraries with bioactive fragment space","volume":"26","author":"Zhang","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cellsig.2020.109775_bb0165","doi-asserted-by":"crossref","first-page":"30443","DOI":"10.1038\/srep30443","article-title":"Human DNA-damage-inducible 2 protein is structurally and functionally distinct from its yeast Ortholog","volume":"6","author":"Siva","year":"2016","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.cellsig.2020.109775_bb0170","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/2211-5463.12491","article-title":"Crystal structure of the retroviral protease-like domain of a protozoal DNA damage-inducible 1 protein","volume":"8","author":"Kumar","year":"2018","journal-title":"FEBS open bio"},{"key":"10.1016\/j.cellsig.2020.109775_bb0175","doi-asserted-by":"crossref","first-page":"33671","DOI":"10.1038\/srep33671","article-title":"Structural studies of the yeast DNA damage-inducible protein Ddi1 reveal domain architecture of this eukaryotic protein family","volume":"6","author":"Trempe","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109775_bb0180","doi-asserted-by":"crossref","first-page":"12494","DOI":"10.1038\/s41598-017-12675-y","article-title":"Multiple regulatory mechanisms of the biological function of NRF3 (NFE2L3) control cancer cell proliferation","volume":"7","author":"Chowdhury","year":"2017","journal-title":"Sci. Rep."},{"issue":"6141","key":"10.1016\/j.cellsig.2020.109775_bb0185","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"341","author":"Martinez Molina","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2020.109775_bb0190","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-pharmtox-010715-103715","article-title":"The cellular thermal shift assay: a novel biophysical assay for in situ drug target engagement and mechanistic biomarker studies","volume":"56","author":"Martinez Molina","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"24","key":"10.1016\/j.cellsig.2020.109775_bb0195","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1021\/jm9704098","article-title":"Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease","volume":"40","author":"Kaldor","year":"1997","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109775_bb0200","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00003495-199856010-00013","article-title":"Nelfinavir, A review of its therapeutic efficacy in HIV infection","volume":"56","author":"Jarvis","year":"1998","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.cellsig.2020.109775_bb0205","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3324\/haematol.2015.135780","article-title":"Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65\/08)","volume":"101","author":"Driessen","year":"2016","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.cellsig.2020.109775_bb0210","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood-2018-05-851170","article-title":"Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma","volume":"132","author":"Driessen","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cellsig.2020.109775_bb0215","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41408-019-0228-2","article-title":"Nelfinavir and lenalidomide\/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I\/II Trial (SAKK 39\/10)","volume":"9","author":"Hitz","year":"2019","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.cellsig.2020.109775_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051065","article-title":"Nelfinavir inhibits the TCF11\/Nrf1-mediated proteasome recovery pathway in multiple myeloma","volume":"12","author":"Fassmannova","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656820302527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656820302527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:01:44Z","timestamp":1760266904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656820302527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":44,"alternative-id":["S0898656820302527"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2020.109775","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2020.109775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109775"}}